News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
707,870 Results
Type
Article (40417)
Company Profile (274)
Press Release (667178)
Multimedia
Podcasts (64)
Webinars (14)
Section
Business (205214)
Career Advice (2024)
Deals (35569)
Drug Delivery (97)
Drug Development (81339)
Employer Resources (172)
FDA (16280)
Job Trends (14943)
News (346791)
Policy (32717)
Tag
Academia (2574)
Accelerated approval (10)
Adcomms (22)
Allergies (95)
Alliances (49917)
ALS (108)
Alzheimer's disease (1452)
Antibody-drug conjugate (ADC) (154)
Approvals (16278)
Artificial intelligence (313)
Autoimmune disease (29)
Automation (19)
Bankruptcy (364)
Best Places to Work (11658)
BIOSECURE Act (20)
Biosimilars (123)
Biotechnology (190)
Bladder cancer (94)
Brain cancer (34)
Breast cancer (367)
Cancer (2881)
Cardiovascular disease (213)
Career advice (1693)
Career pathing (30)
CAR-T (188)
CDC (30)
Cell therapy (507)
Cervical cancer (22)
Clinical research (66992)
Collaboration (1026)
Company closure (3)
Compensation (686)
Complete response letters (23)
COVID-19 (2640)
CRISPR (57)
C-suite (332)
Cystic fibrosis (113)
Data (3004)
Decentralized trials (2)
Denatured (23)
Depression (63)
Diabetes (347)
Diagnostics (6445)
Digital health (23)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (139)
Drug pricing (123)
Drug shortages (28)
Duchenne muscular dystrophy (127)
Earnings (87593)
Editorial (40)
Employer branding (21)
Employer resources (148)
Events (114266)
Executive appointments (853)
FDA (17941)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (941)
Gene editing (131)
Generative AI (22)
Gene therapy (376)
GLP-1 (787)
Government (4516)
Grass and pollen (4)
Guidances (181)
Healthcare (18859)
HIV (40)
Huntington's disease (31)
IgA nephropathy (39)
Immunology and inflammation (152)
Immuno-oncology (9)
Indications (39)
Infectious disease (2814)
Inflammatory bowel disease (153)
Inflation Reduction Act (12)
Influenza (63)
Intellectual property (120)
Interviews (312)
IPO (16624)
IRA (46)
Job creations (3672)
Job search strategy (1436)
Kidney cancer (13)
Labor market (52)
Layoffs (500)
Leadership (18)
Legal (7965)
Liver cancer (79)
Longevity (11)
Lung cancer (400)
Lymphoma (209)
Machine learning (11)
Management (58)
Manufacturing (389)
MASH (90)
Medical device (13476)
Medtech (13481)
Mergers & acquisitions (19665)
Metabolic disorders (851)
Multiple sclerosis (97)
NASH (16)
Neurodegenerative disease (115)
Neuropsychiatric disorders (33)
Neuroscience (2133)
NextGen: Class of 2025 (6553)
Non-profit (4499)
Now hiring (47)
Obesity (428)
Opinion (222)
Ovarian cancer (101)
Pain (107)
Pancreatic cancer (122)
Parkinson's disease (186)
Partnered (22)
Patents (300)
Patient recruitment (166)
Peanut (50)
People (58026)
Pharmaceutical (67)
Pharmacy benefit managers (21)
Phase I (20888)
Phase II (29514)
Phase III (21956)
Pipeline (1640)
Policy (203)
Postmarket research (2564)
Preclinical (8905)
Press Release (64)
Prostate cancer (140)
Psychedelics (37)
Radiopharmaceuticals (253)
Rare diseases (461)
Real estate (5963)
Recruiting (66)
Regulatory (22707)
Reports (50)
Research institute (2334)
Resumes & cover letters (351)
Rett syndrome (9)
RNA editing (9)
RSV (49)
Schizophrenia (86)
Series A (162)
Series B (109)
Service/supplier (13)
Sickle cell disease (60)
Special edition (18)
Spinal muscular atrophy (148)
Sponsored (32)
Startups (3643)
State (2)
Stomach cancer (14)
Supply chain (76)
Tariffs (57)
The Weekly (39)
Vaccines (783)
Venture capital (56)
Weight loss (258)
Women's health (47)
Worklife (16)
Date
Today (95)
Last 7 days (357)
Last 30 days (1844)
Last 365 days (31293)
2025 (16899)
2024 (35331)
2023 (40179)
2022 (51288)
2021 (55834)
2020 (54154)
2019 (46643)
2018 (35126)
2017 (32223)
2016 (31630)
2015 (37707)
2014 (31454)
2013 (26500)
2012 (28771)
2011 (29426)
2010 (27525)
Location
Africa (723)
Alabama (61)
Alaska (7)
Arizona (244)
Arkansas (13)
Asia (38429)
Australia (6280)
California (7475)
Canada (2361)
China (673)
Colorado (322)
Connecticut (318)
Delaware (192)
Europe (82635)
Florida (1119)
Georgia (248)
Hawaii (1)
Idaho (60)
Illinois (641)
India (28)
Indiana (362)
Iowa (16)
Japan (229)
Kansas (110)
Kentucky (29)
Louisiana (14)
Maine (64)
Maryland (1024)
Massachusetts (5550)
Michigan (246)
Minnesota (452)
Mississippi (3)
Missouri (90)
Montana (28)
Nebraska (25)
Nevada (81)
New Hampshire (67)
New Jersey (2082)
New Mexico (28)
New York (2086)
North Carolina (1081)
North Dakota (8)
Northern California (3289)
Ohio (238)
Oklahoma (16)
Oregon (35)
Pennsylvania (1614)
Puerto Rico (17)
Rhode Island (36)
South America (1101)
South Carolina (34)
South Dakota (1)
Southern California (2798)
Tennessee (126)
Texas (1133)
United States (27668)
Utah (220)
Virginia (187)
Washington D.C. (73)
Washington State (636)
West Virginia (4)
Wisconsin (66)
707,870 Results for "prometheus bioscience inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Merck Completes Acquisition of Prometheus Biosciences, Inc.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the Prometheus Biosciences, Inc. (“Prometheus”) (NASDAQ: RXDX) acquisition.
June 16, 2023
·
6 min read
Deals
Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.
Merck, known as MSD outside the United States and Canada, and Prometheus Biosciences, Inc. announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for $200.00 per share in cash for a total equity value of approximately $10.8 billion.
April 16, 2023
·
12 min read
Biotech Beach
Prometheus Laboratories Announces New Health Plan Agreements to Provide Precision-Guided Testing Services
Prometheus Laboratories Inc. announced the execution of provider agreements with three large regional health plans to facilitate access to PredictrPK®, precision-guided biologic testing, and other Prometheus testing services to the participating health plans and their respective members.
May 9, 2024
·
2 min read
Press Releases
Bloom Burton & Co. Inc. Announces Exercise of Satellos Bioscience Inc. Warrants
May 21, 2025
·
1 min read
Press Releases
Forte Biosciences, Inc. Announces Results and Provides Update
May 15, 2025
·
5 min read
Press Releases
Revelation Biosciences, Inc. Announces Pricing of $4 Million Public Offering
May 29, 2025
·
5 min read
Press Releases
Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook
May 8, 2025
·
16 min read
Biotech Beach
Prometheus Biosciences, Inc. Announces Proposed Public Offering of Common Stock
Prometheus Biosciences, Inc. announced that it intends to offer and sell, subject to market and other conditions, $250 million of shares of its common stock in an underwritten public offering.
December 7, 2022
·
4 min read
Press Releases
Parse Biosciences Partners with Japanese Distributor, SCRUM Inc.
April 2, 2025
·
2 min read
Press Releases
Jabez Biosciences, Inc. Announced Phase 1 Clinical Trial of JBZ-001 at AACR 2025
May 12, 2025
·
2 min read
1 of 70,787
Next
